ELI LILLY WEIGHT-LOSS DRUG TRIAL RESULTS LIFT COMPANY STOCK

Eli Lilly shares rose after the company released results from a late-stage clinical trial of its next-generation weight-loss drug. The Campbell's Company also saw its shares edge higher ahead of the United States market open. Campbell's reported adjusted earnings per share for the third quarter that beat the average analyst estimate. The two companies featured among the notable stock movers of the session.

Eli Lilly's trial results relate to a new weight-loss treatment the company is developing beyond its existing obesity drug portfolio. The Campbell's Company, known primarily as a canned soup maker, posted third-quarter adjusted earnings per share above consensus analyst forecasts. Campbell's shares moved upward in pre-market trading following the earnings release. The results placed Campbell's among the outperforming stocks in early United States market activity.

The movements in both Eli Lilly and Campbell's Company shares drew attention from market observers tracking stock movers across the session. Eli Lilly's position in the obesity and weight-loss drug market has grown in significance as demand for such treatments has increased. Campbell's third-quarter beat adds to the financial picture for the company as it continues operating in the consumer food sector. Both stocks were highlighted as part of the broader United States equities session activity.